FDA Stops Sale of Supplements Marketed Under False Drug Claims

This week, the FDA filed a permanent injunction against two Minnesota companies that marketed and sold amino acid supplements as treatments for Parkinson’s, Alzheimer’s and other neurological disorders. To make matters worse, the companies also marketed their “amino-acid therapy” products as treatments for other problems, such as depression, attention-deficit hyperactivity disorder, fibromyalgia and obsessive compulsive disorder.

In July of 2010, the FDA uncovered proof that CHK Nutrition and NeuroResearch Clinics marketed their amino acid products as treatments for neurotransmitter diseases, after completing a routine inspection. The agency immediately issued a warning to the companies, insisting that they stop making unapproved drug claims about their products.

In February, the FDA conducted a follow-up insepction, which revealed that neither company had changed its marketing practices as previously directed. In fact, the FDA found that both companies had continued to engage in false marketing practices using the misleading drug claims. Their review of the companies’ websites revealed an abundant and persistent use of unverified medical claims about the products.

The injunction, which was filed earlier this week, prohibits the companies from distributing any of their amino acid supplements until the drug claims are removed from their websites and cleared by an independent investigator. Until the companies comply with the FDA’s regulations, they will be unable to process or distribute their products.

Bookmark and Share

Comments are closed.